Kamagra enthält Sildenafilcitrat als pharmakologisch aktiven Bestandteil. Dieser hemmt selektiv die Phosphodiesterase-5 und erhöht dadurch die Konzentration von cGMP im Corpus cavernosum. Der Effekt ist zeitlich begrenzt, da die Halbwertszeit von Sildenafil etwa vier Stunden beträgt. In der galenischen Form als Mundgel erfolgt die Resorption besonders rasch, was zu einem schnelleren Wirkeintritt führt. Der Abbau erfolgt überwiegend hepatisch über CYP3A4, wobei ein aktiver Metabolit entsteht, der zur Gesamtwirkung beiträgt. Typische Nebenwirkungen ergeben sich aus der Vasodilatation, darunter leichte Kopfschmerzen und nasale Kongestion. In klinischen Beschreibungen wird kamagra oral jelly im Zusammenhang mit der schnelleren Absorption erwähnt.

Suggestions for the clinical use of pharmacotherapies for smoking cessation

Quit Tobacco Series: Medication Chart‡‡
See FDA package inserts for more information, including more detailed safety information. Ask your doctor if one of these options is right for you. Medication
Cautions/Warnings
Side Effects
Dosage
Use
Availability (check
insurance)
Bupropion
Not for use if you:
* Insomnia
* Days 1-3: 150 mg each
Start 1-2
Prescription Only:
SR 150
* Use monoamine oxidase (MAO) inhibitor
* Dry mouth
* Generic
* Use bupropion in any other form
* Days 4–end: 150 mg
* Have a history of seizures
twice daily
quit date;
* Wellbutrin SR
* Have a history of eating disorders
FDA Boxed Warning:
Nicotine Gum
* Caution with dentures
* 1 piece every 1 to 2 hours
OTC Only:
(2 mg or 4 mg)
* Do not eat or drink 15
soreness
* 6-15 pieces per day
* Generic
minutes before or during use
* Stomach
* If ≤ 24 cigs: 2 mg
* Nicorette
* If ≥ 25 cigs/day: 4 mg
Nicotine Inhaler
* May irritate mouth/throat at
* 6-16 cartridges/day
Prescription Only:
first (but improves with use)
irritation
* Inhale 80 times/cartridge
* Nicotrol inhaler
* May save partially-used
& throat
cartridge for next day
Nicotine Lozenge
* Do not eat or drink 15 minutes before or
* Hiccups
* If smoke ≥ 30 minutes after
OTC Only:
(2 mg or 4 mg)
during use
waking: 2 mg
* Generic
* One lozenge at a time
* Heartburn
* If smoke ≤ 30 minutes after
* Limit 20 in 24 hours
waking: 4 mg
* Weeks 1-6: 1 every 1-2 hrs
* Wks 7-9: 1 every 2-4 hrs
* Wks 10-12: 1 every 4-8 hrs

Nicotine Nasal Spray
* Not for patients with asthma
* 1 “dose” = 1 squirt per nostril
Prescription
* May irritate nose (improves over time)
irritation
* 1 to 2 doses per hour
* May cause dependence
* 8 to 40 doses per day
* Nicotrol NS
* Do NOT inhale
Nicotine Patch
* Do not use if you have severe eczema or
* Local skin
* One patch per day
(7 mg, 14 mg or 21 mg)
psoriasis
reaction
* If ≥ 10 cigs/day: 21 mg 4 wks,
prescription:
* Insomnia
14 mg 2-4 wks, 7 mg 2-4 wks
* Generic
* Nicoderm CQ
* Nicotrol

Varenicline
Use with caution in patients:
* Days 1-3: 0.5 mg every
Prescription only:
* With significant renal impairment
* Insomnia
* Chantix
* With serious psychiatric illness
* Abnormal,
* Days 4-7: 0.5 mg twice daily
* Undergoing dialysis
* Day 8–end: 1 mg twice daily
quit date;
FDA Boxed Warning:
Combinations:
* Only patch + bupropion is currently FDA-
See individual See individual medications above.
See above.
1) Patch + bupropion
approved.
medications
2) Patch + gum
* Follow instructions for individual
3) Patch + [lozenge or inhaler]
medications.
Updated July 2009
ce Guideline Update: Treating Tobacco Use and Dependence, U.S. Public Health Service, May 2008.

Source: http://www.tobaccofreelivingfdl.com/sft818/medicationchart.pdf

Individual variation and the acceptance of average bioequivalence.1993.pdf

SciAnNews Individual Variation and the Acceptance of Average Bioequivalence by Laszlo Endrenyi & Miklos Schulz Drug Information Journal, Vol. 27, pp. 195-201, 1993 0092-8615/93 Printed in the USA. All rights reserved. Copyright (C) 1993 Drug Information Association Inc INDIVIDUAL VARIATION AND THE ACCEPTANCE OF AVERAGE BIOEQUIVALENCE Department of Pharmacology, University of Toro

Http://www.web-anesthesie.fr/site/sommaire/ag_1.htm

Webanesthésie : n°1 - Sommaire - Anesthésie générale : endoprothèses coronaires et . Page 1 sur 11Accueil > Sommaire du n°1 > Anesthésie générale > Endoprothèses coronaires et anesthésie Auteurs : J.-J. Lehot*, G. Rioufol**, P. Ffrench***, M. Cannesson*, Z. Virchova* *Hospices civils de Lyon, service d’anesthésie-réanimation et ERI22 ** Hôpital cardiovasculaire et

Copyright © 2010-2014 Online pdf catalog